Welcome to our dedicated page for Aura Biosciences news (Ticker: AURA), a resource for investors and traders seeking the latest updates and insights on Aura Biosciences stock.
Aura Biosciences, Inc. (NASDAQ: AURA) is a clinical-stage biotechnology company headquartered in Boston, Massachusetts, developing precision therapies for solid tumors that aim to preserve organ function. News about AURA stock frequently centers on clinical trial milestones, regulatory designations, financing activities, and participation in healthcare and investor conferences.
A key theme in Aura’s news flow is progress with its lead candidate, bel-sar (AU-011). The company regularly reports updates on the global Phase 3 CoMpass trial in early or early-stage choroidal melanoma, which it describes as the first registration-enabling study in this indication. Press releases also cover developments in additional ocular oncology programs, including metastases to the choroid and cancers of the ocular surface, and in non-muscle invasive bladder cancer, where Aura has shared Phase 1 data and details of an ongoing Phase 1b/2 trial.
Investors following AURA news can expect recurring coverage of regulatory interactions, such as Orphan Drug and Fast Track designations for bel-sar, as well as financial updates through quarterly and annual results furnished via Form 8-K. Aura’s announcements also include public offering details, cash runway commentary, and information about patent applications for new formulations of bel-sar in urologic oncology.
In addition, Aura frequently announces participation in healthcare and life sciences conferences, fireside chats, and investor events, where senior management discusses the company’s pipeline and strategy. For anyone tracking AURA, this news page provides a centralized view of Aura Biosciences’ clinical progress, corporate developments, and capital markets activity over time.
Aura Biosciences Inc. (NASDAQ: AURA) recently announced that Phase 2 data for its first virus-like drug conjugate (VDC), belzupacap sarotalocan (AU-011), will be presented at the ESMO 2022 Congress, taking place from September 9-13 in Paris. The presentation will focus on the safety of suprachoroidal administration for treating early-stage choroidal melanoma. The company aims to enhance treatment options for this severe form of eye cancer, currently in a dose escalation trial. Additional developments are planned for other oncology applications.
Aura Biosciences Inc. (NASDAQ: AURA) announced recent advancements in its leading candidate, belzupacap sarotalocan (AU-011), aimed at treating early-stage choroidal melanoma. Presentations at the EURETINA Congress will showcase interim safety results from a Phase 2 trial and final efficacy data from a Phase 1b/2 trial. The ongoing development focuses on both choroidal melanoma and its metastatic counterpart. Aura plans to submit an IND for choroidal metastases in the second half of 2022, emphasizing the drug's potential in ocular oncology.
Aura Biosciences (NASDAQ: AURA) reported significant advancements in its clinical pipeline for belzupacap sarotalocan, aiming to treat non-muscle invasive bladder cancer (NMIBC) and early-stage choroidal melanoma. The company is set to dose the first patient in the Phase 1 trial for NMIBC in Q3 2022 and initiate a pivotal trial for choroidal melanoma in Q4 2022. Aura received FDA Fast Track designation for NMIBC, enhancing its development strategy. Financially, the company reported a net loss of $13.5 million for Q2 2022, with cash reserves expected to fund operations into 2024.
Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology firm, announced participation in a fireside chat at the 2022 Hybrid BTIG Biotechnology Conference on August 8, 2022, at 9:00 a.m. ET. The chat will feature CEO Elisabet de los Pinos and CFO Julie Feder. Aura is developing a novel class of virus-like drug conjugates (VDCs) for oncology, including its leading candidate, belzupacap sarotalocan (AU-011), aimed at treating ocular cancers. The company is also pursuing other applications in cancer therapy.
Aura Biosciences, Inc. (NASDAQ: AURA) has received Fast Track designation from the FDA for its drug candidate belzupacap sarotalocan (AU-011), aimed at treating Non-Muscle Invasive Bladder Cancer (NMIBC). This designation facilitates a more efficient development process, enabling frequent communication with the FDA and potential for Priority Review. The planned Phase 1 clinical trial will assess safety and treatment efficacy, with data expected in 2023. Aura also has Fast Track and Orphan Drug designations for AU-011 in choroidal melanoma.
Aura Biosciences Inc. (NASDAQ: AURA) announced results from a retrospective study comparing visual acuity outcomes in early-stage choroidal melanoma patients treated with belzupacap sarotalocan against those receiving plaque radiotherapy. The study indicated significant vision preservation (p = 0.0094) for belzupacap sarotalocan, highlighting the urgent need for effective therapies in this patient population. The Chief Medical Officer emphasized the potential of belzupacap sarotalocan to shift treatment paradigms, with ongoing Phase 2 trials exploring further efficacy.
Aura Biosciences (NASDAQ: AURA) presented data on its virus-like drug conjugate (VDC), belzupacap sarotalocan (AU-011), for treating early-stage choroidal melanoma at the ISOO 2022 Bi-Annual Meeting in the Netherlands. Key findings include updated safety results from a Phase 2 trial using suprachoroidal administration and final efficacy data from a Phase 1b/2 trial with intravitreal administration. Aura plans to finalize the administration route and begin its pivotal program by year's end, underscoring its commitment to vision-preserving therapies.
Aura Biosciences Inc. (AURA) announced the publication of preclinical data for AU-011, its first Virus-Like Drug Conjugate (VDC) candidate, at the 2022 ASCO Annual Meeting. The combination of AU-011 with immune checkpoint inhibitors demonstrated effectiveness against primary tumors and metastases in preclinical models, suggesting potential for treating life-threatening cancers such as choroidal melanoma and non-muscle invasive bladder cancer. The research highlights collaboration with Leiden University Medical Center, enhancing the clinical prospects of AU-011.
Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology firm, has announced participation in two upcoming investor conferences. The first is Cowen's Virtual 3rd Annual Oncology Innovation Summit on June 2, 2022, featuring a fireside chat at 9:00 a.m. ET. The second is the Jefferies Global Healthcare Conference on June 8, 2022, with a presentation at 1:30 p.m. ET. Live webcasts for these events will be available on the company's website, with replays archived for 90 days. Aura is developing virus-like drug conjugates for various oncology indications, currently focusing on AU-011 for ocular cancers.
Aura Biosciences Inc. (NASDAQ: AURA) announced significant clinical milestones for AU-011 in oncology, including the initiation of pivotal trials in choroidal melanoma and phase 1 trials for non-muscle invasive bladder cancer. The company reported Q1 2022 financials, showing a net loss of $12.8 million, up from $5.9 million in Q1 2021. Operating expenses rose due to increased R&D and administrative costs. As of March 31, 2022, Aura had $133.3 million in cash, sufficient to fund operations into 2024. The company maintains a focus on developing VDC therapies for various cancer indications.
FAQ
What is the current stock price of Aura Biosciences (AURA)?
What is the market cap of Aura Biosciences (AURA)?
